Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients

Date

23 Nov 2019

Session

Poster display session

Topics

Targeted Therapy

Tumour Site

Endometrial Cancer

Presenters

Min Kyu Kim

Citation

Annals of Oncology (2019) 30 (suppl_9): ix122-ix130. 10.1093/annonc/mdz431

Authors

M.K. Kim

Author affiliations

  • Obstetrics And Gynecology, Samsung Changwon Hospital Sung Kyun Kwan University, 630-723 - Changwon/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 384P

Background

Microsatellite instability (MSI)test has been found and developed with relationship of HNPCC or Lynch syndrome. Its role has been extended from screening marker for Lynch syndrome detection to response marker for immune checkpoint therapy. We investigated to know prevalence of abnormal microsatellite instability (MSI-L/H) among endometrial cancer ovary cancer.

Methods

We identified 51 cases of MSI samples from ovary and endometrial cancer visiting hereditary gynecologic cancer center.

Results

We found 34 ovary cancer ,13 endometrial cancer and 4 colon cancer patients. Median age was 56.6(18∼78). About thirty percent have family cancer history among patient relatives (14/45(31.1%)). Early stage cancer (I∼II) (4/25,16.0%) have higher incidence than late stage cancer (III∼IV) (2/28,7.1%). Abnormal MSI have three serous type and endometrioid type pathology. Among abnormal MSI, we found two MSI-L and four MSI-H (6/51(11.8%)). We found one MSI-H ovary cancer ,3 MSI-H endometrial cancer patients (1/34(2.9%),3/13(23.1%)).

Conclusions

There are about 10 percent of abnormal MSI in this study group. Prospective large clinical study is needed for hereditary cancer prevention and precision medicine.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.